ALTEOGEN Inc. (196170.KQ) KOE
385,500.00
+31500(+8.90%)
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
385,500.00
+31500(+8.90%)
Currency In KRW
Address
62, Yuseong-daero
Daejeon, 34054
Korea (the Republic of)
Phone
82 4 2384 8780
Website
Sector
Healthcare
Industry
Biotechnology
Employees
145
First IPO Date
December 12, 2014
| Name | Title | Pay | Year Born |
| Soon-Jae Park | Chief Executive Officer | 0 | 1954 |
| Hang Yeon Kim | Chief Financial Officer & Executive Vice President | 0 | 1965 |
| Kyuwan Kim | Senior Vice President & Head of New Drug Development | 0 | N/A |
| Vivek Shenoy | Chief Business Development Officer | 0 | N/A |
| Sang Woo Kang | Senior Vice President of Management Support Group | 0 | N/A |
| Tae-Yon Chun | Executive Vice President & Corporate Alliance Officer | 0 | 1965 |
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.